How many patients with Multiple Sclerosis (MS) do you have personally under your care:

Practice Type:

• Community:
• Academic:
• Private practice:

Of your [X] MS patients, how many patients do you currently have on the following treatments?

• Ocrevus (IV):
• Ocrevus Zunovo (SubQ):
• Kesimpta:
• Briumvi:

How many NEW to anti-CD20 patients did you start/do you plan to start on the following? Do not include patients switching from one anti-CD20 drug to another anti-CD20 drug.

• Ocrevus (IV):
  
  • Past 6 months (#)
  • Next 6 months (#)
    
• Ocrevus Zunovo (SubQ):
  
  • Past 6 months (#)
  • Next 6 months (#)
    
• Kesimpta:Ocrevus (IV):
  
  • Past 6 months (#)
  • Next 6 months (#)
    
• Ocrevus (IV):
  
  • Past 6 months (#)
  • Next 6 months (#)

How many patients have switched in the past 6 months, and how many do you expect to switch in the next 6 months?

• From Ocrevus / Ocrevus Zunovo → Briumvi:
  
  • Past 6 months (#)
  • Next 6 months (#)
    
• From Kesimpta → Briumvi:
  
  • Past 6 months (#)
  • Next 6 months (#)
    
• From Briumvi → Ocrevus / Ocrevus Zunovo / Kesimpta:
  • Past 6 months (#)
  • Next 6 months (#)

Please elaborate on any specific reasons that might lead you to increase or decrease the number of patients starting on Briumvi (new or switch) in the next 6 months compared with the past 6 months? Please be as specific.

Of your patients who were on Ocrevus or Kesimpta before Briumvi coming market, please enter the percentages (%) for the following already switched or expected to switch to Briumvi:

• Ocrevus → Already switched to Briumvi (%):
• Ocrevus → Expected to switch in 2 years (%):
• Kesimpta → Already switched to Briumvi (%):
• Kesimpta → Expected to switch in 2 years (%):

How many patients TOTAL do you expect to have on the 4 branded ANTI-CD20 drugs at the following points in time? Please factor all drivers of patient additions and discontinuations including new to anti-CD20 patient starts, switches to and from other anti-CD20s, and patient discontinuations).

• 1 year from now:
• 2 years from now:
• 5 years from now:

How many patients TOTAL do you expect to have on Briumvi at the following points in time? Please factor all drivers of patient additions and discontinuations including new to anti-CD20 patient starts, switches to and from other anti-CD20s, and patient discontinuations).

• 1 year from now:
• 2 years from now:
• 5 years from now:

Based on your own patient experience, please indicate what the following PERSISTENCE percentages (%) are for Briumvi patients?

• % that persist from the 1st treatment (loading dose + 2 week later dose) to 2nd treatment:
• % that persist from the 2nd treatment to the 3rd treatment:
• % that persist from the 3rd treatment to the 4th treatment:

In your experience, what is the average time interval (in weeks) between when you patients get their Briumvi treatments (label recommends 24 weeks, curious to know your real-world reality)?

How does the ease or difficulty of getting Briumvi approved by insurance compare with that for Ocrevus? Select one.

• Briumvi is much easier than Ocrevus
• Briumvi is a little easier than Ocrevus
• They are about the same
• Briumvi is a little more difficult than Ocrevus
• Briumvi is a lot more difficult than Ocrevus

Considering both your actual hard dollar economics and the effort involved in prescribing the drugs, how do you view Briumvi’s profitability for you personally compared with Ocrevus? Select one.

• Briumvi is much more profitable than Ocrevus
• Briumvi is a little more profitable than Ocrevus
• They are about the same
• Briumvi is a little less profitable than Ocrevus
• Briumvi is much less profitable than Ocrevus
• I have no idea

Compared with Ocrevus, how do you perceive Briumvi in the following dimensions?

Briumvi’s Efficacy, Briumvi’s Safety, Briumvi’s Tolerability

• Much better than Ocervus
• Somewhat better than Ocervus
• About the same
• Somewhat worse than Ocervus
• Much worse than Ocervus

Please detail the key reasons for why patients who end up switching from Ocrevus or Kesimpta to Briumvi are making the switch? Please be specific.

For your new to anti-CD20 patients who select Briumvi over Ocrevus, please allocate 100% to the following reasons for preferring Briumvi:
The total across the 5 options must equal 100%.

• Superior perceived efficacy (including better crap gap):
• Superior perceived tolerability:
• Superior perceived safety (incl not having a breast cancer warning):
• 1-hour infusion time advantage:
• Something else, specify

What are the key one, two, or three studies, developments, or findings in the last year that have played the biggest role in shifting or shaping your preference between Briumvi and Ocrevus?

How broadly, if at all, do you expect to utilize Ocrevus Zunovo in your practice? Please elaborate.

How has the availability of Ocrevus Zunovo impacted the number of patients that you expect to have on BRIUMVI by the end of 2025? Select one.

Do you think that SubQ Briumvi could represent a compelling alternative to Kesimpta? Please explain.

Looking at things 2 years after SubQ Briumvi gets approved, what percentage (%) of your MS patients that decide to go do SubQ route for an anti-CD 20 drug would you envision putting on Sub Q Briumvi (assuming it is priced at a slight discount to Kesimpta and has similar insurance coverage/hurdles)?